Article
Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate.
Journal of hepatology - 1 May 2015
Charuworn Prista, Hengen Paul N, Aguilar Schall Raul, Dinh Phillip, Ge Dongliang, Corsa Amoreena, Reesink Hendrik W, Zoulim Fabien, Kitrinos Kathryn M
Abstract excerpt
BACKGROUND AND AIMS: HBsAg loss is a desired, but rare, treatment-induced clinical endpoint in chronic hepatitis B (CHB). Few studies have evaluated viral factors contributing to HBsAg loss. METHODS: This study evaluated baseline interpatient sequence diversity across the HBV genome in tenofovir disoproxil fumarate-treated patients who lost HBsAg and compared it to that of control patients with high HBsAg levels...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
